Introduction
Current achievement in immunology promoted the immune cells as powerful therapeutic antigens, targeting tumor antigens with T cells expressing chimeric antigen receptors (CARs), especially in lymphoid malignancies patients.(1-3) However, a potentially fatal cytokine release syndrome was reported in a significant number of subjects and requiring intensive care unit (ICU) admission. Then, despites its promising results in treating cancer, this give a big challenge to enact it available for a larger number of patients. (4) Increasingly considered as promising immunotherapeutic agents for cancer, Natural Killer (NK) cells have advantages because they are potentially broadly applicable and do not cause graft-versus-host disease such as other T cells counterparts.(5) NK cells have an important role in cancer immunosurveillance as a part of innate immune system.(6,7) They don't need peptide antigen to be presented in major histocompatibility complex (MHC) molecules foregoing, because their activity were controlled by distinct germline-encoded cell surface receptors so the healthy and diseased tissue can be distinguished. (8, 9) The problem is, in cancer patients, the immunosuppressive tumor microenvironment was generally impaired, so the NK cell responses were also impaired. That's why current NK cell therapies were commonly performed with allogeneic adoptive transfer from a suitable donor's NK cell which had expanded ex vivo. (10) (11) (12) Primary NK cells usually have a limited of life span and expansion potential, but the NK cell line NK-92, with help of interleukin (IL)-2 can be continuously expanded in a good manufacturing practices (GMP)-compliant process. (13) Early phase clinical trials for safety and clinical activity of NK-92 cells for allogeneic therapy in patients with advanced malignancies showed a good result. (13) (14) (15) Preclinical studies using both NK-92 primary human NK cells and investigating the generating of cluster of differentiation (CD)19-specific chimeric antigen receptors (+) NK cells. (16) (17) (18) By that, compared than limited original T cells (17) (18) (19) (20) (21) , CAR-engineered cells can be isolated and expanded from bulk of non-transduced cells (19) (20) (21) (22) . Thus, donor-derived allogeneic cells immunotherapy were being preferred for adoptive cancer because the cells do not recognize tumor cells as 'self', and can bypassing inhibitory signals. (10, 11) This advantage may be extended to NK-92 cells that do not express most of the inhibitory killer cell immunoglobulin-like receptors (KIRs) and phenotypically resemble activated NK cells. (5, 23) This approach could be potentially utilized for solid tumor or hemotological malignancies cases, where CAR-engineered NK-92 cells will target antigens expressed by cancer cells. (17, 19, 20, (24) (25) (26) (27) (28) Human Natural Killers Cells T cell receptor (TCR) and antibody/B cell receptor (BCR) produced by the site-specific somatic recombination of these cells. (29) NK cells first illustrated as large granular lymphocytes, and has natural cytotoxicity to counter tumor cells. Later on people recognized NK cells as a separate lymphocyte lineage with cytokine-producing effector function besides its cytotoxicity ( Figure 1 ). (29, 30) NK cell activity regulation including the NK cell detection system involving the activation of a variety of cell surface and the inhibitory receptors. There will be an equilibrium between the integration of antagonistic pathways upon interaction with neighboring cells to decide the activation of NK cells to kill target cells.(31) When activated, NK cell receptors will detect a distress on cells ligands, for example the stress-induced self ligands which recognized by some slert molecules like the NK group 2D (NKG2D). (32) There are also alert molecules such as nonself ligands (the cytomegalovirus-encoded m157 recognized by Ly49H in the mouse) and Toll-like receptor (TLR) ligands. Naturally, NK cells express several TLRs which can induces interferon (IFN)-γ production and enhances cytotoxicity in vitro. (33) Like any other lymphocytes, during their development NK cell acquire tolerance to self. This does not always occur but NK cell have the potential to attack normal self cells. (34) NK cells utilize the absence mensuration of consecutively
The immune system is divided into two parts, called the acquired immune system and the innate immune system. Innate immunity was typically characterized with a broadly distributed variety of myeloid and lymphoid cells and the rapid responses through a defined repository of germlineencoded receptors. In the contrary, adaptive immunity in mammals was defined by two lymphocytes, T and B cells. (44), activate antigen-presenting cell (APC) for MHC class I further upregulate expression (47) , activate macrophages to kill the restricted intracellular pathogens (48) , and anti-proliferating effect on viral and malignant-transformed cells (49) .
NK cells in human is phenotypically and functionally heterogeneous. NK cells which were rich with CD56 + surface molecules were primarily cytokine-secreting cells, found about 10% NK cells found in blood, and almost 100% in secondary lymphoid tissues. They can be activated within minutes to secrete cytokines and chemokines, but these CD3
+ cells barely can spontaneously kill tumor cell targets. (50) Otherwise, Circulating NK cells with low surface density (called dim expression of CD56 and NKp46) does not express cytokines as agile as the other type but some, but not all, have the ability to lyse susceptible tumor cell targets sprightly.(51) however both types have relatively distinct and balanced important roles during human immune response.(52-55) despite its cytokine secretion or cytotoxicity, NK cell was tightly regulated by the balancing of its activation and inhibition signals which are integrated in a complex network expressed from its cell surface receptors, and we have the ideas that the immune system can be engineered to cure some forms of cancer. (56) 
Targeting NK Cells in Cancer Immunotherapy
Formerly, people pit most attention at T lymphocytes for immunotherapy strategies, but new discoveries showed the potential of NK cells as better effector cells for treating cancer. The cytotoxicity effects, together with cytokine secretion, especially IFN and granulocyte-macrophage colony-stimulating factor, assign them at the crossroads of innate and adaptive immunity. Through antibody-mediated cellular cytotoxicity, the activity of monoclonal antibody can be enhancing and can be transfected with chimeric antigen receptors. There are still challenges including to consistently obtain sufficient numbers of cells for patient treatment, as we know NK cells only present approximately 10% of all lymphocytes in the blood, and the other issue is to remove T cells which can induce Graft versus host disease (GvHD) in the recipient, commonly using negative CD3 depletion using immunomagnetic antibody tagging with subsequent absorption of the cells over a magnetic column (i.e., the Miltenyi CliniMACS system, Bergisch-Gladbach, Germany). (68, 69) Recently the interest shifted to NK cells from umbilical cord blood which is readily available with no risk or aggravation for donor. Frozen cord blood cells either cryopreserved or not, can serve as starting material. NK cells in cord blood are immature, so they must be cultured for several weeks with a cocktail of cytokines which contains a combination of IL-2, IL-15, FMS-like tyrosine kinase 3 ligand (Flt-3L) and IL-3 on positively selected cord blood NK cells were placed on a feeder layer of mesenchymal stromal cells, until reach an acceptable NK cell numbers, average at a median of 60-fold. (57, 70) However, this expansion process is costly and burdensome, restricted process in a GMP-standard laboratory, performed in gas-permeable bags, in flasks or in bioreactors that expand larger cell numbers on a smaller footprint. To reduce the cost, any manipulation must be done before culture expansion, so the material and time cost will be less. The bag system is a good choice for it does not need wide spaces for sterile and closed system. Some company offers automated technology for cell expansion including Milteny's Prodigy (Miltenyi Biotec GmbH, BergischGladbach, Germany) with their closed system in constant medium and cytokine feed as per program, and the G-Rex biorecator (Wilson Wolf Manufacturing, New Brighton, MN, USA) expands NK cells well and simplified medium change as the cells collect at the bottom of the flask. (71) Furthermore, with the help of cytokines and certain growth factors, adoptively transferred NK cells can be expanded and activated in vivo in conditioned patients, or may also combined with other treatment modalities to reach a synergistic antitumor activities. (72) Recalling the cytotoxic features of NK cells as part of innate immunity system, they don't need prior sensitization to kill any virally infected cells and tumor cells. Adequate number of functional NK cells that are able to proliferate in vivo were needed for an effective therapy but are not overstimulated by cytokines.(73,74) Some group study attempt to optimizing methods for NK cells ex vivo isolation, activation and expansion from peripheral blood, mainly for prevention and/or treatment of relapsed disease. (75, 76) Another study using IL-2 and an artificial antigen presenting cell to expand umbilical cord blood NK cells ex vivo. (78) Particularly, there are two ongoing clinical trials testing the feasibility (NCT01619761 and NCT01729091). Apheresis become the most preferred method for collecting PBMNCs due to its ability to collect cells aseptically into a closed system and minimizing the contamination. (79) Previous experiences demonstrated that concomitant administration of cytokines such as IL-2, for NK cells autologous infusion are clinically ineffective (65) , then the focus shifted to allogeneic therapy. In this case, graftversus-host disease in the recipient have to be prevented, by adding some manipulation steps in expansion process. (68) Substantial donor-dependent variability also found in terms of NK cell yield, so a continuously growing NK cell line is needed to provide predictable numbers of highly cytotoxic NK cells on expansion. (15, 68, 69, (80) (81) (82) the cryopreservation procedure selected the most potent UCB CD34 + cells, leading to a higher fold expansion (600 versus 200) therefore generated a higher NK cell numbers, not regarding the phenotype, cytokine production or cytotoxicity of the cells. (83, 84) NK cell proliferation ex vivo can generally be stimulated using a feeder cell such as monocytes which stimulate NK cell expansion by both humoral signals and direct cell-to-cell contact. That's why some protocols suggest the using of PBMNCs as a source of feeder cells in the NK cell culture. (65, (85) (86) (87) Moreover, two allogeneic feeder cell lines commonly used in NK cell expansion including an Epstein-Barr virus-transformed lymphoblastoid cell line and an engineered leukemic cell line that express a membranebound form of IL-15 fused to the T cell receptor CD8a and the 41BB ligand.(88-90) Using allogeneic feeder cell lines requires irradiation, meanwhile autologous feeder cell lines do not need it. (69, (88) (89) (90) (91) NK-92 is a highly potent permanent NK cell line (NantKwest, Culver City, CA, USA), which is now readily available, processed from a cGMP-compliant master cell bank, predictable and reproducible amplification of an extensively characterized potent NK cell agent is at hand for clinical usage. (94) NK-92 cells can be easily manipulated genetically for specific tumor antigens recognition, or to develop antibodydependent cellular cytotoxicity. It has low risks and can be easily infused into patients, even in the advanced stage of cancer.(4) NK cell can be engineered to express many different CARs to prevent tumor resistance, by targeting for instance, CD19 or CD20 (anti-B cell malignancies), CD38 (anti-myeloma) or human epidermal growth factor receptor 2 (HER2; ErbB2; anti-epithelial cancers), with lower costs compared to autologous or allogeneic NK cells and, particularly, CAR-T cells make it as a promising effective treatments in cancer.(5) 
CAR-expressing NK Cells
On August 2017, the forst CAR-T therapy approved in United States was Kymriah (tisagenlecleucel) from Novartis. Without a phase 3 trial and within just six month the approval was achieved, due to the astonishing patients' clinical responses. After three months' treatment with Kymriah, ~83% of pediatric and adult patients (up to 25 years old) 25 with relapsed or refractory B cell acute lymphoblastic leukemia (ALL) showed sufficient remission and curative therapy are adequate. In that event, soon Kite Pharma was acquired by Gilead Sciences, as a sign the industry believe that Kymriah will lead to other CARs. For CAR-T itself, a successfully overcome immunosuppressive tumor microenvironments, address the heterogeneity of solid tumors and incorporate a wider range of antigens suitable for tumor targeting, to treat leukemia auspiciously. (95) NK cells may serve as a better alternative than CARdriven cytolysis. Allogeneic NK cells will induce the immune response and then be rejected after few days, while autologous NK cells will disappear after few days in line with its lifetime. Superior rather than T cells, NK cells' spontaneous cytotoxicity activity can trigger the demise of target cells in a tumor associated antigens (TAA)-unrestricted manner via specific natural cytotoxicity receptors (NCRs), including NCR3 (also known as NKp30), NCR2 (also known as NKp44), NCR1 (also known as NKp46), and killer cell lectin-like receptor subfamily K, member 1 (KLRK1, best known as NKG2D). The potential NK cells currently has been translated into clinical-scale using cGMP using a variety of starting materials, technologies, and manipulations.(68) The cell line NK-92 as the most potent and promising therapeutic cell stand as master cell, thoroughly standardized and characterized.(82) After irradiation, it can be infused allogeneic to patients. (14) to ensure the product's safety, quality control become an important part include sterility testing, viability, gram stain, mycoplasma testing (for long-term cultures and products utilizing animal-derived reagents), endotoxin testing (LAL Kinetic-QCL, Lonza, Walkersville, MD) and sorting the cell phenotype as determined by flow cytometry. (68, 107) Another challenge for successful therapy with NK cells in mainstream clinical applications include to find the most efficient and optimal method to yield enough cells that clinically relevant, i.e., with highest tumor cytotoxicity level. The exciting future was saw as NK cells immunotherapy now marching from treating hematologic malignancy to solid tumor as well. The challenge ahead is how to optimally activate NK cells endogenously without the use of a cell infusion, perhaps by utilizing IL-15 or any promising proteins. (108) Conclusion NK cells as a part of immune system play a role in the first defense against diseases, including malignancies. NK cells provide an immediate natural response of cytolytic action. Recently, cell-based therapies increasingly favored and important as the promising treatment for cancer. An improved understanding of NK cell character and mechanism will promote to a clinical applications of this approach. Eventually, it might even discovered that both these cell types have their place in the multimodal approach that is required to eliminate cancer and control its recurrence.
